A detailed history of Mercer Global Advisors Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 40,397 shares of LYEL stock, worth $49,284. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,397
Previous 42,792 5.6%
Holding current value
$49,284
Previous $95,000 38.95%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.3 - $3.01 $3,113 - $7,208
-2,395 Reduced 5.6%
40,397 $58,000
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $73,174 - $131,371
42,792 New
42,792 $95,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $302M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.